RUSTY DURAN: Open Payments
NPI 1528570538 · YORKTOWN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,470 in 141 payments from 18 companies in 2025. Trend: 2023 $1,776 · 2024 $1,583 · 2025 $2,470
Food & beverage: $2,358Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $443 |
| Vanda Pharmaceuticals Inc. | 19 | $302 |
| ABBVIE INC. | 26 | $279 |
| Otsuka America Pharmaceutical, Inc. | 12 | $268 |
| Neurocrine BioSciences, Inc. | 20 | $252 |
| Teva Pharmaceuticals USA, Inc. | 10 | $215 |
| Alkermes, Inc. | 9 | $177 |
| E.R. Squibb & Sons, L.L.C. | 7 | $150 |
| Axsome Therapeutics, Inc. | 5 | $91 |
| Lundbeck LLC | 3 | $63 |
Products named: CAPLYTA, FANAPT, VRAYLAR, REXULTI, INGREZZA, ARISTADA, COBENFY, AUSTEDO XR.
Industry payments across VA — which companies pay providers there.
